The genetic basis of ankylosing spondylitis

Current Opinion in Rheumatology

Volumn 18, Issue 4, 2006, Pages 332-341

  Reveille, John D ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Genetics; Genomewide scans; HLA B27; Interleukin 1; Spondylitis

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANDROGEN RECEPTOR; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CD14 ANTIGEN; CYTOCHROME P450 2D6; HLA ANTIGEN CLASS 1; HLA B27 ANTIGEN; HLA B35 ANTIGEN; HLA B38 ANTIGEN; HLA B39 ANTIGEN; HLA B60 ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN; REGULATOR PROTEIN; STROMELYSIN; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

AMINO ACID SEQUENCE; ANKYLOSING SPONDYLITIS; CHROMOSOME 10Q; CHROMOSOME 16Q; CHROMOSOME 19Q; CHROMOSOME 3Q; CHROMOSOME 6P; CHROMOSOME MAP; GENE LINKAGE DISEQUILIBRIUM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

CHROMOSOME MAPPING; CHROMOSOMES, HUMAN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; SPONDYLITIS, ANKYLOSING;

EID: 33748070192     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000231899.81677.04     Document Type: Review

References (119)

1. Schlosstein L, Terasaki PI, Bluestone R, Pearson CM. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med 1973; 288:704-706.
2. Brewerton DA, Hart FD, Nicholls A, et al. Ankylosing spondylitis and HL-A 27. Lancet 1973; 1:904-907.
3. Laval SH, Timms A, Edwards S, et al. Whole-genome screening in ankylosing spondylitis: evidence of non-MHC genetic-susceptibility loci. Am J Hum Genet 2001; 68:918-926.
4. Brown MA, Pile KD, Kennedy LG, et al. A genome-wide screen for susceptibility loci in ankylosing spondylitis. Arthritis Rheum 1998; 41:588-595.
5. Zhang G, Luo J, Bruckel J, et al. Genetic studies in familial ankylosing spondylitis susceptibility. Arthritis Rheum 2004; 50:2246-2254.
6. Miceli-Richard C, Zouali H, Said-Nahal R, et al. Significant linkage to spondyloarthropathy on 9q31-34. Hum Mol Genet 2004; 13:1641-1648.
7. Reveille JD, Brown MA. Pathogenesis of ankylosing spondylitis. In: Weisman MH, Reveille JD, van der Heijde D, editors. Ankylosing spondylitis and the spondyloarthropathies. Philadelphia: Mosby; 2006. p. 28.
8. Montserrat V, Marti M, Lopez de Castro JA. Allospecific T cell epitope sharing reveals extensive conservation of the antigenic features of peptide ligands among HLA-B27 subtypes differentially associated with spondyloarthritis. J Immunol 2003; 170:5778-5785.
9. Goodall JC, Ellis L, Hill-Gaston JS. Spondyloarthritis-associated and non spondyloarthritis-associated B27 subtypes differ in their dependence on tapasin for surface expression and their incorporation into the peptide loading complex. Arthritis Rheum 2006; 54:139-147. An interesting analysis of the behavior of B*2704 and B*2705 in comparison with B*2706 and B*2709 during the loading of endogenous peptide onto the complex of HLA class I heavy chain that suggests that the ability to exhibit optimal cell surface expression in the absence of tapasin is not a prerequisite for susceptibility to AS.
10. Kuon W, Holzhutter HG, Appel H, et al. Identification of HLA-B27-restricted peptides from the Chlamydia trachomatis proteome with possible relevance to HLA-B27-associated diseases. J Immunol 2001; 167:4738-4746.
11. Borrego F, Masilamani M, Kabat J, et al. The cell biology of the human natural killer cell CD94/NKG2A inhibitory receptor. Mol Immunol 2005; 42:485-488.
12. Dangoria NS, DeLay ML, Kingsbury DJ, et al. HLA-B27 misfolding is associated with aberrant intermolecular disulfide bond formation (dimerization) in the endoplasmic reticulum. J Biol Chem 2002; 277:23459-23468.
13. Bird LA, Peh CA, Kollnberger S, et al. Lymphoblastoid cells express HLA-B27 homodimers both intracellularly and at the cell surface following endosomal recycling. Eur J Immunol 2003; 33:748-759.
14. Kollnberger S, Bird L, Sun MY, et al. Cell-surface expression and immune receptor recognition of HLA-B27 homodimers. Arthritis Rheum 2002; 46:2972-2982.
15. Ekman P, Saarinen M, He Q, et al. HLA-B27-transfected (Salmonella permissive) and HLA-A2-transfected (Salmonella nonpermissive) human monocytic U937 cells differ in their production of cytokines. Infect Immun 2002; 70:1609-1614.
16. Inman RD, Payne U. Determinants of synoviocyte clearance of arthritogenic bacteria. J Rheumatol 2003; 30:1291-1297.
17. Boyle LH, Goodall JC, Opat SS, Gaston JS. The recognition of HLA-B27 by human CD4(+) T lymphocytes. J Immunol 2001; 167:2619-2624.
18. Boyle LH, Gaston JS. Breaking the rules: the unconventional recognition of HLA-B27 by CD4+ T lymphocytes as an insight into the pathogenesis of the spondyloarthropathies. Rheumatology (Oxford) 2003; 42:404-412.
19. van der Linden SM, Valkenburg HA, de Jongh BM, Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 1984; 27:241-249.
20. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998; 41:58-67.
21. Brown MA, Kennedy LG, MacGregor AJ, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum 1997; 40:1823-1828.
22. Brown MA, Laval SH, Brophy S, Calin A. Recurrence risk modeling of the genetic susceptibility to ankylosing spondylitis. Ann Rheum Dis 2000; 59:883-886.
23. Pimtanothai N, Rizzuto GA, Slack R, et al. Diversity of alleles encoding HLA-B40: relative frequencies in united states populations and description of five novel alleles. Hum Immunol 2000; 61:808-815.
24. Robinson WP, van der Linden SM, Khan MA, et al. HLA-Bw60 increases susceptibility to ankylosing spondylitis in HLA-B27+ patients. Arthritis Rheum 1989; 32:1135-1141.
25. Rubin LA, Amos CI, Wade JA, et al. Investigating the genetic basis for ankylosing spondylitis. Linkage studies with the major histocompatibility complex region. Arthritis Rheum 1994; 37:212-220.
26. Brown MA, Pile KD, Kennedy LG, et al. HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann Rheum Dis 1996; 55:268-270.
27. Wei JC, Tsai WC, Lin HS, et al. HLA-B60 and B61 are strongly associated with ankylosing spondylitis in HLA-B27-negative Taiwan Chinese patients. Rheumatology (Oxford) 2004; 43:839-842.
28. Yamaguchi A, Tsuchiya N, Mitsui H, et al. Association of HLA-B39 with HLA-B27-negative ankylosing spondylitis and pauciarticular juvenile rheumatoid arthritis in Japanese patients. Evidence for a role of the peptide-anchoring B pocket. Arthritis Rheum 1995; 38:1672-1677.
29. Wagener P, Zeidler H, Eckert G, Deicher H. Increased frequency of HLA-Bw62 and Bw35 CREG antigens HLA-B27 negative ankylosing spondylitis. Z Rheumatol 1984; 43:253-257.
30. Singal DP, Li J, Zhang G. Microsatellite polymorphism of the MICA gene and susceptibility to rheumatoid arthritis. Clin Exp Rheumatol 2001; 19:451-452.
31. Ricci-Vitiani L, Vacca A, Potolicchio I, et al. MICA gene triplet repeat polymorphism in patients with HLA-B27 positive and negative ankylosing spondylitis from Sardinia. J Rheumatol 2000; 27:2193-2197.
32. Yabuki K, Ota M, Goto K, et al. Triplet repeat polymorphism in the MICA gene in HLA-B27 positive and negative Caucasian patients with ankylosing spondylitis. Hum Immunol 1999; 60:83-86.
33. Martinez-Borra J, Gonzalez S, Lopez-Vazquez A, et al. HLA-B27 alone rather than B27-related class I haplotypes contributes to ankylosing spondylitis susceptibility. Hum Immunol 2000; 61:131-139.
34. Brown MA, Kennedy LG, Darke C, et al. The effect of HLA-DR genes on susceptibility to and severity of ankylosing spondylitis. Arthritis Rheum 1998; 41:460-465.
35. Said-Nahal R, Miceli-Richard C, Gautreau C, et al. The role of HLA genes in familial spondyloarthropathy: a comprehensive study of 70 multiplex families. Ann Rheum Dis 2002; 61:201-206.
36. Monowarul-Islam SM, Numaga J, Fujino Y, et al. HLA-DR8 and acute anterior uveitis in ankylosing spondylitis. Arthritis Rheum 1995; 38:547-550.
37. Ploski R, Flato B, Vinje O, et al. Association to HLA-DRB1*08, HLA-DPB1*0301 and homozygosity for an HLA-linked proteasome gene in juvenile ankylosing spondylitis. Hum Immunol 1995; 44:88-96.
38. Barron KS, Reveille JD, Carrington M, et al. Susceptibility to Reiter's syndrome is associated with alleles of TAP genes. Arthritis Rheum 1995; 38:684-689.
39. Kuipers JG, Raybourne RB, Williams KM, et al. Specificities of human TAP alleles for HLA-B27 binding peptides. Arthritis Rheum 1996; 39:1892-1895.
40. Fraile A, Collado MD, Mataran L, et al. TAP1 and TAP2 polymorphism in Spanish patients with ankylosing spondylitis. Exp Clin Immunogenet 2000; 17:199-204.
41. Paulsson KM. Evolutionary and functional perspectives of the major histocompatibility complex class I antigen-processing machinery. Cell Mol Life Sci 2004; 61:2446-2460.
42. Vargas-Alarcon G, Gamboa R, Zuniga J, et al. Association study of LMP gene polymorphisms in Mexican patients with spondyloarthritis. Hum Immunol 2004; 65:1437-1442.
43. Maksymowych WP, Adlam N, Lind D, Russell AS. Polymorphism of the LMP2 gene and disease phenotype in ankylosing spondylitis: no association with disease severity. Clin Rheumatol 1997; 16:461-465.
44. Fraile A, Nieto A, Vinasco J, et al. Association of large molecular weight proteasome 7 gene polymorphism with ankylosing spondylitis. Arthritis Rheum 1998; 41:560-562.
45. Rudwaleit M, Siegert S, Yin Z, et al. Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis 2001; 60:36-42.
46. McGarry F, Walker R, Sturrock R, Field M. The -308.1 polymorphism in the promoter region of the tumor necrosis factor gene is associated with ankylosing spondylitis independent of HLA-B27. J Rheumatol 1999; 26:1110-1116.
47. Milicic A, Lindheimer F, Laval S, et al. Interethnic studies of TNF polymorphisms confirm the likely presence of a second MHC susceptibility locus in ankylosing spondylitis. Genes Immun 2000; 1:418-422.
48. Hohler T, Schaper T, Schneider PM, et al. Association of different tumor necrosis factor alpha promoter allele frequencies with ankylosing spondylitis in HLA-B27 positive individuals. Arthritis Rheum 1998; 41:1489-1492.
49. Verjans GM, Brinkman BM, Van Doornik CE, et al. Polymorphism of tumour necrosis factor-alpha (TNF-alpha) at position -308 in relation to ankylosing spondylitis. Clin Exp Immunol 1994; 97:45-47.
50. Gonzalez S, Torre-Alonso JC, Martinez-Borra J, et al. TNF-238A promoter polymorphism contributes to susceptibility to ankylosing spondylitis in HLA-B27 negative patients. J Rheumatol 2001; 28:1288-1293.
51. Vargas-Alarcon G, Londono JD, Hernandez-Pacheco G, et al. Heat shock protein 70 gene polymorphisms in Mexican patients with spondyloarthropathies. Ann Rheum Dis 2002; 61:48-51.
52. Carter KW, Pluzhnikov A, Timms AE, et al. Meta-analysis of three whole genome linkage scans for ankylosing spondylitis. Arthritis Rheum 2005; 52(Suppl):S241.
53. Hamersma J, Cardon LR, Bradbury L, et al. Is disease severity in ankylosing spondylitis genetically determined? Arthritis Rheum 2001; 44:1396-1400.
54. Brown MA, Brophy S, Bradbury L, et al. Identification of major loci controlling clinical manifestations of ankylosing spondylitis. Arthritis Rheum 2003; 48:2234-2239.
55. Kim TH, Stone MA, Rahman P, et al. Interleukin 1 and nuclear factor-kappaB polymorphisms in ankylosing spondylitis in Canada and Korea. J Rheumatol 2005; 32:1907-1910. No differences of IL-1α, IL-1β, IL-1Ra, and NF-κB polymorphisms between AS patients and controls were seen in these populations, although at least in the Toronto cohort the small number of patients examined do not rule out a false negative due to power concerns.
56. Maksymowych WP, Rahman P, Reeve JP, et al. Association of the IL1 gene cluster with susceptibility to ankylosing spondylitis: an analysis of three Canadian populations. Arthritis Rheum 2006; 54:974-985.
57. Djouadi K, Nedelec B, Tamouza R, et al. Interleukin 1 gene cluster polymorphisms in multiplex families with spondylarthropathies. Cytokine 2001; 13:98-103.
58. Jin L, Zhang G, Akey JM, et al. Lack of linkage of IL1RN genotypes with ankylosing spondylitis susceptibility. Arthritis Rheum 2004; 50:3047-3048.
59. Timms AE, Crane AM, Sims AM, et al. The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis. Am J Hum Genet 2004; 75:587-595.
60. Chou C-T, Timms AE, Wei JC, et al. Replication of association of IL-1 gene complex members with ankylosing spondylitis in Taiwanese Chinese. Ann Rheum Dis 2005 Dec 16; [Epub ahead of print]. This group finds association of AS with all the five IL-1 region SNPs studied (IL-1F10.3, IL-1RN.4 and IL-1RN.VNTR), though IL-1A was not studied here.
61. Maksymowych WP, Reeve JP, Reveille JD, et al. High-throughput single-nucleotide polymorphism analysis of the IL1RN locus in patients with ankylosing spondylitis by matrix-assisted laser desorption ionization-time-of- flight mass spectrometry. Arthritis Rheum 2003; 48:2011-2018.
62. Sims AM, Timms A, Pointon JJ, et al. Fine-mapping of the IL-1 gene cluster pinpoints genetic associations with ankylosing spondylitis. Arthritis Rheum 2005; 59:S576.
63. Albuquerque S, Zhang G, Zhou X, et al. Association of IL-1 genes with ankylosing spondylitis susceptibility. Evidence from family-based analyses. Arthritis Rheum 2005; 52:F35/529.
64. Ravindran JS, Owen P, Lagan A, et al. Interleukin 1alpha, interleukin 1beta and interleukin 1 receptor gene polymorphisms in psoriatic arthritis. Rheumatology (Oxford) 2004; 43:22-26.
65. Beyeler C, Armstrong M, Bird HA, et al. Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis 1996; 55:66-68.
66. Brown MA, Edwards S, Hoyle E, et al. Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. Hum Mol Genet 2000; 9:1563-1566.
67. Sampson HW. Spondyloarthropathy in progressive ankylosis (ank/ank) mice: morphological features. Spine 1988; 13:645-649.
68. Krug HE, Wietgrefe MM, Ytterberg SR, et al. Murine progressive ankylosis is not immunologically mediated. J Rheumatol 1997; 24:115-122.
69. Krug HE, Taurog JD. HLA-B27 has no effect on the phenotypic expression of progressive ankylosis in ank/ank mice. J Rheumatol 2000; 27:1257-1259.
70. Tsui FW, Tsui HW, Cheng EY, et al. Novel genetic markers in the 5′-flanking region of ANKH are associated with ankylosing spondylitis. Arthritis Rheum 2003; 48:791-797.
71. Tsui HW, Inman RD, Paterson AD, et al. ANKH variants associated with ankylosing spondylitis: Gender differences. Arthritis Res Ther 2005; 7:513-525. This group has extended their original observation, finding gender differences in the role of ANKH in susceptibility to AS. Given the lack of confirmation from the Oxford group of their previous study, clearly more work is needed in other groups.
72. Timms AE, Zhang Y, Bradbury L, et al. Investigation of the role of ANKH in ankylosing spondylitis. Arthritis Rheum 2003; 48:2898-2902.
73. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599-603.
74. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411:603-606.
75. Mielants H, Veys EM, Cuvelier C, De VM. Macroscopic and histological changes of the ileum HLA-B27 related diseases: therapeutic consequences. Int J Clin Pharmacol Res 1984; 4:409-414.
76. Crane AM, Bradbury L, van Heel DA, et al. Role of NOD2 variants in spondylarthritis. Arthritis Rheum 2002; 46:1629-1633.
77. Archer JR. Ankylosing spondylitis, IgA, and transforming growth factors. Ann Rheum Dis 1995; 54:544-546.
78. McGarry F, Cousins L, Sturrock RD, Field M. A polymorphism within the transforming growth factor beta 1 gene is associated with ankylosing spondylitis (AS). Rheumatology (Oxford) 2001; 41 (Suppl 1):16.
79. Jaakkola E, Crane AM, Laiho K, et al. The effect of transforming growth factor β1 gene polymorphisms in ankylosing spondylitis. Rheumatology (Oxford) 2003; 43:32-38.
80. van der Paardt M, Crusius JB, Garcia-Gonzalez MA, et al. Susceptibility to ankylosing spondylitis: no evidence for the involvement of transforming growth factor beta 1 (TGFB1) gene polymorphisms. Ann Rheum Dis 2005; 64:616-619. A rather small negative study of TGFB1 SNPs in Dutch AS patients. On the basis of this study and others, little role for this locus in AS susceptibility is apparent.
81. Howe HS, Cheung PL, Kong KO, et al. Transforming growth factor beta-1 and gene polymorphisms in oriental ankylosing spondylitis. Rheumatology (Oxford) 2005; 44:51-54.
82. Jin L, Weisman M, Zhang G, et al. Lack of association of matrix metalloproteinase 3 (MMP3) genotypes with ankylosing spondylitis susceptibility and severity. Rheumatology (Oxford) 2005; 44:55-60. A moderate-sized study of MMP3 SNPS in families and unrelated patients with AS. No association was seen of any of the MMP3 SNPs with functional impairment in AS.
83. Kaluza W, Leirisalo-Repo M, Marker-Hermann E, et al. IL10.G microsatellites mark promoter haplotypes associated with protection against the development of reactive arthritis in Finnish patients. Arthritis Rheum 2001; 44:1209-1214.
84. Goedecke V, Crane AM, Jaakkola E, et al. Interleukin 10 polymorphisms in ankylosing spondylitis. Genes Immun 2003; 4:74-76.
85. Collado-Escobar MD, Nieto A, Mataran L, et al. Interleukin 6 gene promoter polymorphism is not associated with ankylosing spondylitis. J Rheumatol 2000; 27:1461-1463.
86. Linssen A, Rothova A, Broekema N, et al. Genes on chromosome 14q and their role in the pathogenesis of HLA-B27 associated diseases. Clin Exp Rheumatol 1987; 5 (Suppl 1):S89-S95.
87. Broekema N, Linssen A, Luyendijk L, et al. Association of Gm allotypes with the occurrence of ankylosing spondylitis in HLA-B27-positive anterior uveitis. Am J Ophthalmol 1986; 102:549.
88. Kijlstra A, Linssen A, Ockhuizen T. Association of Gm allotypes with the occurrence of ankylosing spondylitis in HLA-B27-positive anterior uveitis. Am J Ophthalmol 1984; 98:732-735.
89. Gran JT, Teisberg P, Olaissen B, et al. HLA-B27 and allotypes of complement components in ankylosing spondylitis. J Rheumatol 1984; 11:324-326.
90. Demaine AG, Panayi GS, Vaughan RW, et al. Immunoglobulin allotypes in psoriasis, psoriatic arthropathy and ankylosing spondylitis. Exp Clin Immunogenet 1984; 1:61-65.
91. Mierau R, von Muhlen CA, Zarnowski H, et al. Immunoglobulin allotype Gm(1,2;21) in ankylosing spondylitis with peripheral arthritis. Ann Rheum Dis 1988; 47:893-897.
92. Brown MA, Rudwaleit M, Pile KD, et al. The role of germline polymorphisms in the T-cell receptor in susceptibility to ankylosing spondylitis. Br J Rheumatol 1998; 37:454-458.
93. Mori K, Ushiyama T, Inoue K, Hukuda S. Polymorphic CAG repeats of the androgen receptor gene in Japanese male patients with ankylosing spondylitis. Rheumatology (Oxford) 2000; 39:530-532.
94. van der Paardt M, Crusius JB, de Koning MH, et al. No evidence for involvement of the Toll-like receptor 4 (TLR4) A896G and CD14-C260T polymorphisms in susceptibility to ankylosing spondylitis. Ann Rheum Dis 2005; 64:235-238. A negative study of CD14 C-260T and TLR4 A896G polymorphisms in Dutch ankylosing spondylitis patients. However, due to the rather small sample size and the growing importance of toll-like receptor polymorphisms in other diseases, it would be premature to exclude this locus in ankylosing spondylitis susceptibly at this time based on these data.
95. Miceli-Richard C, Zouali H, Lesage S, et al. CARD15/NOD2 analyses in spondylarthropathy. Arthritis Rheum 2002; 46:1405-1406.
96. Ferreiros-Vidal I, Amarelo J, Barros F, et al. Lack of association of ankylosing spondylitis with the most common NOD2 susceptibility alleles to Crohn's disease. J Rheumatol 2003; 30:102-104.
97. D'Amato M. The Crohn's associated NOD2 3020InsC frameshift mutation does not confer susceptibility to ankylosing spondylitis. J Rheumatol 2002; 29:2470-2471.
98. Kim TH, Rahman P, Jun JB, et al. Analysis of CARD15 polymorphisms in Korean patients with ankylosing spondylitis reveals absence of common variants seen in western populations. J Rheumatol 2004; 31:1959-1961.
99. Orozco G, Garcia-Porrua C, Lopez-Nevot MA, et al. Lack of association between ankylosing spondylitis and a functional polymorphism of PTPN22 proposed as a general susceptibility marker for autoimmunity. Ann Rheum Dis 2006; 65:687-688. Apparently the PTPN22 association with other systemic autoimmune disease does not carry over to AS, at least in this small-to-moderately sized cohort.
100. Seo JS, Lee SS, Kim SI, et al. Influence of VEGF gene polymorphisms on the severity of ankylosing spondylitis. Rheumatology (Oxford) 2005; 44:1299-1302. A moderate sized study of VEGF SNPs in Korean AS patients - essentially a negative study, except for a possible association with cervical spine involvement.
101. Sierakowski S, Chwiecko J, Kita K. Alpha-1-antitrypsin phenotypes in patients with ankylosing spondylitis. Rocz Akad Med Bialymst 2001; 46:54-59.
102. Buisseret PD, Pembrey ME. Less of MH alpha 1-antitrypsin phenotypes in rheumatoid arthritis and ankylosing spondylitis. Lancet 1977; 2:1358-1359.
103. Moller P, Fagerhol MK. Pi phenotypes in patients with ankylosing spondylitis, acute anterior uveitis, psoriasis and chronic prostatitis. Clin Genet 1984; 26:339-341.
104. Pal A, Hill M, Wordsworth P, Brown M. Secretor status and ankylosing spondylitis. J Rheumatol 1998; 25:318-319.
105. Smith GW, James V, Mackenzie DA, et al. Ankylosing spondylitis and secretor status: a re-evaluation. Br J Rheumatol 1997; 36:778-780.
106. Shinebaum R. ABO blood group and secretor status in the spondyloarthropathies. FEMS Microbiol Immunol 1989; 1:389-395.
107. van der Paardt M, Crusius JB, Garcia-Gonzalez MA, et al. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in ankylosing spondylitis. Rheumatology (Oxford) 2002; 41:1419-1423.
108. McGarry F, Neilly J, Anderson N, et al. A polymorphism within the interleukin 1 receptor antagonist (IL-1Ra) gene is associated with ankylosing spondylitis. Rheumatology (Oxford) 2001; 40:1359-1364.
109. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995; 99:303-310.
110. Hurme M, Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are coordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 1998; 28:2598-2602.
111. Rahman P, Peddle L, Sun S, et al. IL-1 locus on chromosome 2q confers susceptibility on psoriatic arthritis. Arthritis Rheum 2005; 52:S692.
112. Rudwaleit M, Siegert S, Yin Z, et al. Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis 2001; 60:36-42.
113. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996; 273:1516-1517.
114. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000; 405:847-856.
115. Suzuki A, Yamada R, Chang X, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003; 34:395-402.
116. Begovich AB, Carlton VE, Honigberg LA, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004; 75:330-337.
117. Styrkarsdottir U, Cazier JB, Kong A, et al. Linkage of osteoporosis to chromosome 20p12 and association to BMP2. PLoS Biol 2003; 1:E69.
118. Allen M, Heinzmann A, Noguchi E, et al. Positional cloning of a novel gene influencing asthma from chromosome 2q14. Nat Genet 2003; 35:258-263.
119. Botstein D, Risch N. Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex diseases. Nature Genetics 2003; 33 (Suppl):228-237.